Activity Overview
This online, on-demand virtual symposium brings together renowned experts in psychiatry. In this educational program, these experts discuss long-acting injectables (LAIs) for the treatment of patients with schizophrenia as well as best practices for motivational interviewing. This program also includes an interview with a patient who has spent years dealing with mental health issues and the use of LAIs.
This educational activity is an archive of the live virtual symposium held on October 2, 2026.
System requirements for this online activity are available here.
The activity is free to all users.
Target Audience
This educational activity is directed toward psychiatrists, psychiatric nurse practitioners, physician assistants, registered nurses, pharmacists, and other health care providers involved in the management of patients with schizophrenia.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Analyze clinical trial data for long-acting injectable agents for schizophrenia
- Integrate counseling strategies for long-acting injectable medications into individualized management plans for patients with schizophrenia
Christoph U. Correll, MD
Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
Hempstead, NY
Professor and Chair, Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy
Charité - Universitätsmedizin Berlin
Berlin, Germany
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Alkermes, Allergan, Angelini, Aristo, Autobahn, Axsome, Boehringer Ingelheim, Bristol Myers Squibb, Cerevel Therapeutics, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Draig, EuMentis Therapeutics, Gedeon Richter, GH Research, Hetero, Hikma, Holmusk, Intra-Cellular Therapies, Jamjoom Pharma, Janssen/Johnson & Johnson, Karuna, LB Pharma, Lilly, Lundbeck, MapLight, MedinCell, MedLink, Merck, Mindpax, Mitsubishi Tanabe Pharmaceuticals, Mylan, Neumora Therapeutics, Neuraxpharm, Neurelis, Neurocrine, Neurosterix, NeuShen, Neusignal Therapeutics, Newron, Noven, Novo Nordisk, Orion Pharma, Otsuka, PPD Biotech, Recognify Life Sciences, Recordati, Relmada, Response Pharmaceutical, Revival, Roemmers, Rovi, Saladax, Sanofi, Seqirus, Servier, Sumitomo Pharma America, Sun Pharma, Sunovion, Supernus, Tabuk, Takeda, Terran, Teva, Tolmar, Vertex, Viatris, Xenon; Grant/Research Funding (to institution): Boehringer Ingelheim, Janssen, Takeda; Ownership Interests in Publicly Traded Companies: LB Pharmaceuticals; Ownership Interests in Privately Held Companies: Cardio Diagnostics, Kuleon Bioscience, MedLink Global, Mindpax, Quantic, Terran; Royalty or Patent Benefits: UpToDate
Jose M. Rubio, MD, PhD
Assistant Professor of Psychiatry
Institute of Behavioral Science
Feinstein Institutes for Medical Research
Glen Oaks, NY
Disclosures: Advisor, Consultant, Fee for Service Recipient: Bristol Myers Squibb, Karuna, Teva; Grant/Research Funding (to institution): Alkermes, Neurocrine, Saladax; Royalty or Patent Benefits: UpToDate
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Physicians Education Resource®, LLC is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This Application-based activity is approved for a maximum of 1.0 contact hour (1.0 CEU) under UAN # 0661-0000-26-032-H01-P This UAN # expires 01/31/2028.
Eligibility for credits requires full engagement with the enduring activity, completion of the post-activity assessment questions, completion and submission of the activity evaluation, NABP e-pid # and month/date of birth within 30 days of activity completion. No partial credits are given.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Johnson & Johnson Innovative Medicine.